PREVENTION OF ADVERSE OUTCOMES OF RHEUMATOID ARTHRITIS: MODERN THERAPEUTIC STRATEGY
- 作者: Chichasova N.V.1, Chichasova NV1
-
隶属关系:
- 期: 编号 6 (2012)
- 页面: 49-56
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279452
- ID: 279452
如何引用文章
全文:
详细
The article discusses the problem of modern therapeutic tactics in the treatment of rheumatoid arthritis (RA), a one of the most serious human diseases. The practice in the early application of the disease-modifying anti-rheumatic drugs (DMARDs) for improvement of long-term outcomes of the disease, which became possible after the development of new diagnostic criteria EULAR / ACR (2010) for RA is considered. International recommendations for management of patients with early arthritis and for the treatment strategies for RA are presented. Particular attention is given to a new class of drugs for the treatment of RA - genetically engineered biological substances that have an impact on the various links of the pathogenesis of the disease directly in the synovium and are used in combination therapy with DMARDs, particularly methotrexate. Thus, improvement of long-term outcomes of RA depends on the timely diagnosis of the disease, early treatment with DMARDs, appropriate assessment of the significance of symptomatic therapy, and tight control of the results of therapy with the timely correction of treatment.
参考
- Фоломеева О.М., Амирджанова В.Н. Исследование функциональной активности при ревматоидном артрите // Ревматология 1989. № 1. С. 55-61.
- Fex E, Larsen BM, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and leisure time activities in patients followed 8 years from onset. J Rheumatol 1998;25(1):44-50.
- Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989;79:67-95.
- Pincus T, Callahan LF. Early mortality in RA predicted by poor clinical status. Bull Rheum Dis 1992;41(4):1-4.
- Arnrett FC, Edworth SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
- Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-88.
- Smolen JS, Landeve R, Breedveld FC, et al. "EULAR recommendation for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs" Ann Rheum Dis 2010;69:964-75.
- Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international force. Ann Rheum Dis 2010;69:631-37.
- Grigor C, Capell H, Stirling A, et al. Effect of treatment strategy of tight control of rheumatoid arthritis (the TIСORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-69.
- Korpela M, Laansonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from FIN-RACo study. Arthr Rheum 2004;50:2072-81.
- Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
- Verstappen SMM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-49.
- Bakker MF, Jacobs WC, Welsing PMJ, et.al. Early clinical response to treatment predict 5-year outcome in RA patients: follow-up results from the CAMERA st4. Ann Rheum Dis 2011;70:1099-103.
- Классификация ревматоидного артрита, принятая на Пленуме Ассоциации ревматологов России 30 сентября 2007 г. // Научно-практ. ревм. 2008. № 1.
- Prevoo ML, 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995;38:44-8.
- Чичасова Н.В., Имаметдинова Г.Р., Амирджанова В.Н., Насонов Е.Л. Методы оценки поражения суставов, активности заболевания, функционального состояния и эффекта терапии у больных ревматоидным артритом. М., 2010. 60 с.
- Weinblatt ME. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheum 1995;34(2):43-8.
- Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheum 2003;21(31):178-85.
- Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Results of a six-month, multicenter, randomized, double-blind, controlled phase IV trial. Arth Rheum 2008;58(1):73-81.
- Ревматология: клинические рекомендации / Под редакцией Е.Л. Насонова. М., 2010.
- Jones G, Sebba A, Gu J, et al. Comparison of tozilisumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69(1):88-96.
- Weinblatt M, Fleischmann R, Emery P. Efficacy and safety of Certolisumab Pegol in a clinically representative population of patients with active rheumatoid arthritis: results of the REALISTIC phase IIIb randomized controlled study" 2010 American College of Rheumatology Annual Meeting, 1805.
- Kristenen LE, Kapetanovic MC, Guffe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008;47(4):495-99.
- Smolen J, van der Heijde DMFM, Clair EW St, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant Infliximab: Results from the ASPIRE trial. Arthr Rheum 2006;54:702-10.
- Hyrych KL, Watson KD, Silman AJ, D.P.M. Symmons and the BSR Biologic Register "Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45(12):1558-65.
- Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
- Bathn JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
- St Clair EW, van der Heijde DM, Smolen JS, et al. For the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. "Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial". Arthr Rheum 2004;50:3432-43.
- Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthr Rheum 2002;46:1443-50.
- Smolen JS, van der Heijde DMFM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Arthr Rheum 2006;54:702-10.
- Vastesaeger N, Aletaha D, St Clair W, et al. Matrix risk model for prediction of rapid radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2008;67(II):63.
- Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthr Rheum 2007;56:3226-35.
补充文件
![](/img/style/loading.gif)